ATE462973T1 - Diagnose und prävention der krebszellinvasion - Google Patents

Diagnose und prävention der krebszellinvasion

Info

Publication number
ATE462973T1
ATE462973T1 AT03763885T AT03763885T ATE462973T1 AT E462973 T1 ATE462973 T1 AT E462973T1 AT 03763885 T AT03763885 T AT 03763885T AT 03763885 T AT03763885 T AT 03763885T AT E462973 T1 ATE462973 T1 AT E462973T1
Authority
AT
Austria
Prior art keywords
prevention
cancer cell
cell invasion
diagnosis
malignant disorders
Prior art date
Application number
AT03763885T
Other languages
English (en)
Inventor
Axel Ullrich
Pjotr Knyazev
Tatjana Knyazeva
Yuri Cheburkin
Peter Vajkoczy
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE462973T1 publication Critical patent/ATE462973T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT03763885T 2002-07-17 2003-07-17 Diagnose und prävention der krebszellinvasion ATE462973T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02015944A EP1382969A1 (de) 2002-07-17 2002-07-17 Diagnose und Behandlung der Invasion von Krebszellen
PCT/EP2003/007786 WO2004008147A2 (en) 2002-07-17 2003-07-17 Diagnosis and prevention of cancer cell invasion

Publications (1)

Publication Number Publication Date
ATE462973T1 true ATE462973T1 (de) 2010-04-15

Family

ID=29762643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03763885T ATE462973T1 (de) 2002-07-17 2003-07-17 Diagnose und prävention der krebszellinvasion

Country Status (11)

Country Link
US (2) US8277802B2 (de)
EP (4) EP1382969A1 (de)
JP (2) JP5419316B2 (de)
CN (2) CN102349997A (de)
AT (1) ATE462973T1 (de)
AU (2) AU2003250984B2 (de)
CA (1) CA2493111C (de)
DE (1) DE60331921D1 (de)
DK (1) DK1530724T3 (de)
ES (1) ES2343950T3 (de)
WO (1) WO2004008147A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
US7108983B1 (en) 1999-04-09 2006-09-19 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker
AU2003286746A1 (en) 2002-10-29 2004-05-25 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
CA2604884A1 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Ddr2 in cancer diagnosis, detection and treatment
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
ES2529790T3 (es) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
US20100255004A1 (en) * 2007-04-13 2010-10-07 Dana Farber Cancer Institute Receptor tyrosine kinase profiling
WO2009005813A1 (en) * 2007-07-02 2009-01-08 Wyeth Modulators of axl for use in treating bone disorders
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (de) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modifizierte antikörperkonstantregion
JP2011522212A (ja) * 2007-10-19 2011-07-28 セル・シグナリング・テクノロジー・インコーポレイテツド 癌の分類および使用法
CA2705164A1 (en) * 2007-11-12 2009-05-22 U3 Pharma Gmbh Axl antibodies
KR101568051B1 (ko) * 2007-11-15 2015-11-10 추가이 세이야쿠 가부시키가이샤 Ａｎｅｘｅｌｅｋｔｏ에 결합하는 단일클론항체, 및 그의 이용
EP2275443B1 (de) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen bindendes molekül, das dazu in der lage ist, wiederholt zwei oder mehr antigenmoleküle zu binden
WO2010014755A1 (en) * 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
WO2010103388A2 (en) * 2009-03-13 2010-09-16 Bergen Teinologioverforing As Method
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
JP5909442B2 (ja) * 2009-05-11 2016-04-26 ユー３・ファーマ・ゲーエムベーハー ヒト化ａｘｌ抗体
EP2270053A1 (de) * 2009-05-11 2011-01-05 U3 Pharma GmbH Humanisierte AXL-Antikörper
RU2011151069A (ru) * 2009-05-15 2013-06-20 Чугаи Сейяку Кабусики Кайся Анти-axl антитело
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
WO2011014872A2 (en) * 2009-07-31 2011-02-03 The Johns Hopkins University Compositions and methods for diagnosing, treating or preventing neoplasias
PT3241840T (pt) 2010-01-22 2022-10-13 Univ Leland Stanford Junior Inibição da sinalização de axl em terapêutica anti-metastática
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
CA2794731C (en) 2010-06-18 2019-03-19 Genentech, Inc. Anti-axl antibodies and methods of use
JP2013535694A (ja) 2010-08-19 2013-09-12 ハワード フローリー インスティチュート 神経病理学的疾患の検出および調節におけるｔａｍ受容体およびｔａｍ受容体リガンド
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
WO2012096933A1 (en) * 2011-01-10 2012-07-19 Trustees Of Dartmouth College Methods for screening for drug resistance in cancer treatment
US9409988B2 (en) 2011-06-22 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
JP6033293B2 (ja) 2011-06-22 2016-11-30 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 抗Ａｘｌ抗体及びその使用
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
US9499856B2 (en) 2012-04-02 2016-11-22 The Board Institute, Inc. DDR2 mutations in squamous cell lung cancer
PT3326622T (pt) 2012-12-14 2021-04-07 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6195716B2 (ja) * 2013-02-15 2017-09-13 富士レビオ株式会社 抗癌剤耐性診断マーカー
US10377984B2 (en) 2013-11-27 2019-08-13 Kaneka Corporation Cell culture medium and culture method using the same
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
WO2015103495A1 (en) * 2014-01-03 2015-07-09 Blanchette Rockefeller Neurosciences Institute Convergence of aggregation rate with validated peripheral diagnostics for alzheimer's disease
ES3034398T3 (en) 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
JP2017205021A (ja) * 2014-09-26 2017-11-24 Jsr株式会社 初代癌細胞のスフェロイド作製方法、スフェロイド、スクリーニング方法、及び、診断方法
US10137173B2 (en) 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
EP3233119A2 (de) 2014-12-18 2017-10-25 Bergen Teknologioverforing AS Antagonistische anti-axl-antikörper
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
AU2017248644B2 (en) 2016-04-15 2019-10-31 Bioatla, Llc Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
TWI851939B (zh) 2016-05-13 2024-08-11 美商拜奧亞特拉公司 抗-ror2抗體、抗體片段、其免疫結合物及其用途
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
KR102905343B1 (ko) 2017-01-18 2025-12-29 바이오아트라, 인코퍼레이티드 Axl 또는 ror2에 대한 키메라 항원 수용체 및 이의 사용 방법
WO2018183703A1 (en) 2017-03-31 2018-10-04 NeuroDiagnostics LLC Lymphocyte-based morphometric test for alzheimer's disease
CN110536703B (zh) 2017-04-20 2024-07-12 Adc治疗有限公司 使用抗axl抗体-药物缀合物的组合疗法
JP7029745B2 (ja) * 2017-12-05 2022-03-04 国立大学法人金沢大学 膠芽腫マーカー及びその使用
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
IL297132A (en) 2020-04-08 2022-12-01 Bergenbio Asa axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE4110405A1 (de) * 1991-03-28 1992-10-01 Birchmeier Walter Prof Dr Verfahren zum nachweis der differenzierung und der invasivitaet von karzinomzellen
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
JP4214537B2 (ja) * 1996-08-12 2009-01-28 セルジーン コーポレーション 新規な免疫治療薬とこの薬物を使用してサイトカインレベルを抵減する方法
AU5077100A (en) * 1999-06-10 2001-01-02 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Non-human transgenic animals deficient in gas6 function and their use
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2001030964A2 (en) * 1999-10-22 2001-05-03 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AU3041701A (en) * 1999-12-23 2001-07-09 Exiqon A/S Therapeutic uses of lna-modified oligonucleotides
EP1272217A1 (de) * 2000-04-13 2003-01-08 Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) Verwendung von inhibierung von gas6 funktion oder gas6 rezeptor für die prävention und behandlung von kardiovaskulären erkrankungen
JP2004537261A (ja) 2000-12-08 2004-12-16 イプソゲン 候補遺伝子のアレイを用いた原発性乳がんの遺伝子発現プロファイリング
CA2528669A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
JP2011024580A (ja) 2011-02-10
AU2003250984A1 (en) 2004-02-02
EP2228654A2 (de) 2010-09-15
ES2343950T3 (es) 2010-08-13
WO2004008147A3 (en) 2004-05-27
EP2267454A3 (de) 2011-03-30
DK1530724T3 (da) 2010-08-02
CA2493111C (en) 2016-07-05
JP2005532805A (ja) 2005-11-04
AU2003250984B2 (en) 2009-10-08
US8277802B2 (en) 2012-10-02
AU2009251103B2 (en) 2013-09-05
CN102349997A (zh) 2012-02-15
AU2009251103A1 (en) 2010-01-21
EP1530724B1 (de) 2010-03-31
CA2493111A1 (en) 2004-01-22
EP2267454A2 (de) 2010-12-29
DE60331921D1 (de) 2010-05-12
EP1530724A2 (de) 2005-05-18
CN1739030A (zh) 2006-02-22
EP1382969A1 (de) 2004-01-21
US20130084300A1 (en) 2013-04-04
WO2004008147A2 (en) 2004-01-22
US20050186571A1 (en) 2005-08-25
JP5419316B2 (ja) 2014-02-19
EP2228654A3 (de) 2011-01-05

Similar Documents

Publication Publication Date Title
DE60331921D1 (de) Diagnose und prävention der krebszellinvasion
EP1578380A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
TNSN05300A1 (en) Treatment with anti-vegf antibodies
WO2003087831A3 (en) Proteins involved in breast cancer
EP2006298A3 (de) Jugendliches Hämochromatose-Gen (HFE2A), Expressionsprodukte und Verwendungen davon
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
EP1578371A4 (de) Zusammensetzungen und verfahren für die tumor-diagnose und behandlung
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
EP1515982A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
ATE413902T1 (de) Patientenüberwachungssystem
EP1409549A4 (de) Zusammensetzungen und verfahren für die diagnose und behandlung von tumoren
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
EP1583504A4 (de) Verfahren und zusammensetzungen für diagnose, prognose und behandlung von krebs
IL162201A0 (en) New methods for diagnosis and treatment of tumours
NO20054744L (no) Behandling av Alzheimers sykdom
IL163900A (en) Antibody which binds to tpte for use in diagnosing, monitoring, preventing or treating cancer disease and pharmaceutical compositions comprising said antibody
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
EP1546182A4 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
EP1608967A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
EP1756166A4 (de) Diagnose und behandlung von prostatakrebs
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
PT1606233E (pt) Derivados de esteres lipidicos de nucleotidos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties